Cite
HARVARD Citation
Nie, R. et al. (2019). Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials. European journal of cancer. pp. 1-11. [Online].